Research ArticleTheranostics
Open Access
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Dominik Mumberg, Karl Ziegelbauer and Alan S. Cuthbertson
Journal of Nuclear Medicine September 2019, 60 (9) 1293-1300; DOI: https://doi.org/10.2967/jnumed.118.223701
Katrine Wickstroem
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Urs B. Hagemann
2Bayer AG, TRG-Oncology II, Berlin, Germany; and
Véronique Cruciani
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Antje M. Wengner
2Bayer AG, TRG-Oncology II, Berlin, Germany; and
Alexander Kristian
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Christine Ellingsen
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Gerhard Siemeister
2Bayer AG, TRG-Oncology II, Berlin, Germany; and
Roger M. Bjerke
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Jenny Karlsson
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Olav B. Ryan
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Lars Linden
3Bayer AG Pharmaceuticals Division, Wuppertal, Germany
Dominik Mumberg
2Bayer AG, TRG-Oncology II, Berlin, Germany; and
Karl Ziegelbauer
2Bayer AG, TRG-Oncology II, Berlin, Germany; and
Alan S. Cuthbertson
1Thorium Conjugate Research, Bayer American Samoa, Oslo, Norway
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 9
September 1, 2019
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Dominik Mumberg, Karl Ziegelbauer, Alan S. Cuthbertson
Journal of Nuclear Medicine Sep 2019, 60 (9) 1293-1300; DOI: 10.2967/jnumed.118.223701
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Dominik Mumberg, Karl Ziegelbauer, Alan S. Cuthbertson
Journal of Nuclear Medicine Sep 2019, 60 (9) 1293-1300; DOI: 10.2967/jnumed.118.223701
Jump to section
Related Articles
Cited By...
- Glypican-3-Targeted 227Th {alpha}-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
- Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
- Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
- Combination Strategies to Improve Targeted Radionuclide Therapy
- Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
- EBV encoded miRNA BART8-3p promotes radioresistance in nasopharyngeal carcinoma by regulating ATM/ATR signaling pathway